Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research
- Conditions
- Relapsed Non-Hodgkin Lymphoma
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06049381
Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
- Conditions
- Hospital-acquired PneumoniaAntibiotic Resistant Infection
- Interventions
- Other: prognosis status
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 4000
- Registration Number
- NCT06028217
Real-World Study of DLBCL With Different Genetic Subtypes
- Conditions
- DLBCL - Diffuse Large B Cell LymphomaLymphoma
- Interventions
- Other: Other
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 10000
- Registration Number
- NCT06026488
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Artificial Intelligence (AI) Analysis of Synchronized Phonocardiography (PCG) and Electrocardiogram(ECG)
- Conditions
- Heart Failure
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 3000
- Registration Number
- NCT06009718
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong School of Medicine, Shanghai, China
🇨🇳Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China
🇨🇳Shanghai East Hospital, Shanghai, China
The Impact of Coagulation Disorders on the Diagnosis and Prognosis of Sepsis
- Conditions
- SepsisCoagulation Disorder
- Interventions
- Diagnostic Test: Early general coagulation function (5 items of coagulation) and thromboelastogram monitoring
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 552
- Registration Number
- NCT05998733
- Locations
- 🇨🇳
Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Regional Lymph Node Irradiation for High-risk pN0 Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Radiation: Regional lymph node radiotherapyRadiation: chest/whole breast irradiation
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1355
- Registration Number
- NCT05976412
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai jiaotong univestigy school of medicine, Shanghai, Shanghai, China
The Role of Bifidobacterium Intervention in Food Allergic Infants
- Conditions
- Food Allergy in Infants
- Interventions
- Dietary Supplement: Bifidobacterium M-16VOther: allergy food avoidance
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT05965063
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Genetic: 84-gene penal
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05934864
- Locations
- 🇨🇳
Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China
🇨🇳Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Sichuan, China
🇨🇳Henan Cancer Hospital, Henan, China
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
- Conditions
- CNS Lymphoma
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT05926427
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05923879
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China